Quantcast
Last updated on April 24, 2014 at 6:40 EDT

Oncothyreon Obtains Anti-Bcl-2 Compound from Sanford-Burnham Medical Research Institute; License Will Expand Oncology Product Development Pipeline

September 12, 2011

SEATTLE, WA and LA JOLLA, CA, Sept. 12, 2011 /PRNewswire/ – Oncothyreon Inc.
(Nasdaq: ONTY) and Sanford-Burnham Medical Research Institute
(Sanford-Burnham) today announced that they have entered into an
exclusive licensing agreement for sabutoclax and related compounds.
Sabutoclax is a pan-inhibitor of the Bcl-2 family of anti-apoptotic
proteins currently in pre-clinical development. Financial terms of the
agreement were not disclosed.

“Overexpression of one or more members of the Bcl-2 family of proteins
is common in most human cancers,” said Scott Peterson, Ph.D., Vice
President of Research and Development at Oncothyreon.  “This
overexpression prevents the type of cell death known as apoptosis,
resulting in resistance to many frequently used cancer treatments.  By
blocking Bcl-2 protein function, sabutoclax induces apoptosis in tumor
cells and increases the activity of chemotherapy. Sabutoclax inhibits
all of the Bcl-2 protein family members, which may prove advantageous
when compared with other compounds directed at these targets.”

Sabutoclax was discovered as a result of research in the laboratories of
Maurizio Pellechia, Ph.D. and John C. Reed, M.D, Ph.D. at
Sanford-Burnham.  Dr. Reed, who has extensively published on the role
of Bcl-2 proteins in cancer, is Chief Executive Officer of
Sanford-Burnham. Reed commented, “We are confident that we have found a
strong development partner in the Oncothyreon team that is dedicated to
advancing sabutoclax into the clinic for patients battling with
cancer.” 

“We are excited to expand our pipeline of small molecule compounds being
developed in oncology,” said Robert L. Kirkman, M.D., President and
Chief Executive Officer at Oncothyreon.  “Maintaining and advancing a
diverse pipeline of both targeted small molecules and therapeutic
vaccines for the treatment of cancer is an integral component of our
corporate strategy.”

About Sanford-Burnham

Sanford-Burnham Medical Research Institute is dedicated to discovering
the fundamental molecular causes of disease and devising the innovative
therapies of tomorrow. Sanford-Burnham, with operations in California
and Florida, is one of the fastest-growing research institutes in the
country. The Institute ranks among the top independent research
institutions nationally for NIH grant funding and among the top
organizations worldwide for its research impact. From 1999 – 2009,
Sanford-Burnham ranked #1 worldwide among all types of organizations in
the fields of biology and biochemistry for the impact of its research
publications, defined by citations per publication, according to the
Institute for Scientific Information.  According to government
statistics, Sanford-Burnham ranks #2 nationally among all organizations
in capital efficiency of generating patents, defined by the number of
patents issued per grant dollars awarded.

Sanford-Burnham utilizes a unique, collaborative approach to medical
research and has established major research programs in cancer,
neurodegeneration, diabetes, and infectious, inflammatory, and
childhood diseases.  The Institute is especially known for its
world-class capabilities in stem cell research and drug discovery
technologies. Sanford-Burnham is a nonprofit public benefit
corporation. For more information, please visit www.sanfordburnham.org.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development
of innovative therapeutic products for the treatment of cancer.
Oncothyreon’s goal is to develop and commercialize novel synthetic
vaccines and targeted small molecules that have the potential to
improve the lives and outcomes of cancer patients. For more
information, visit www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon’s investors with an understanding of its
current intentions and future prospects, this release contains
statements that are forward looking, including statements related to
future preclinical and clinical development plans for our product
candidates. These forward-looking statements represent Oncothyreon’s
intentions, plans, expectations and beliefs and are based on its
management’s experience and assessment of historical and future trends
and the application of key assumptions relating to future events and
circumstances.

Forward-looking statements involve risks and uncertainties, including
risks and uncertainties related to Oncothyreon’s business and the
general economic environment. Many of these risks and uncertainties are
beyond Oncothyreon’s control. These risks, uncertainties and other
factors could cause our actual results to differ materially from those
projected in forward-looking statements. Risks, uncertainties, and
assumptions include those predicting the outcome of preclinical
studies, the ability to advance a preclinical drug candidate into
clinical trials, the timing and results of regulatory reviews, the
safety and efficacy of our product candidates, and the indications for
which our product candidates might be developed. There can be no
guarantee that the results of preclinical studies or clinical trials
will be predictive of either safety or efficacy in future clinical
trials. These and other risks and uncertainties are described in the
reports and other documents filed by Oncothyreon Inc. with the SEC
and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements
contained herein are reasonable, it can give no assurance that its
expectations are correct. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. For a
detailed description of the risks and uncertainties associated with
Oncothyreon, you are encouraged to review the official corporate
documents filed with the securities regulators in the United States on
U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation
to (and expressly disclaims any such obligation to) update or alter its
forward-looking statements whether as a result of new information,
future events, or otherwise.

SOURCE Oncothyreon Inc.


Source: PR Newswire